ERBB2 and breast cancer: In trastuzumab-refractory HER2+ metastatic BC patients, a combination of trastuzumab, pembrolizumab, and chemotherapy resulted in long-lasting clinical responses (20), demonstrating the power of targeting HER2 and PD-1/PD-L1 signaling pathways simultaneously.